Company Overview of Artielle ImmunoTherapeutics, Inc.
Artielle ImmunoTherapeutics, Inc., a biopharmaceutical company, develops recombinant T-cell receptor ligands (RTLs) to treat T-cell mediated inflammatory diseases. It develops RTL1000, a compound for the treatment of multiple sclerosis. The company focuses on the development of therapeutics for the treatment of autoimmune diseases that include multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, optic neuritis, and other diseases. Artielle ImmunoTherapeutics, Inc. was founded in 2004 and is based in Tigard, Oregon.
9020 SW Washington Square Road
Tigard, OR 97223
Founded in 2004
Key Executives for Artielle ImmunoTherapeutics, Inc.
Similar Private Companies By Industry
|Pristine Pharma Corporation||United States|
|Astellas Pharma US, Inc.||United States|
|Boehringer Ingelheim Pharmaceuticals, Inc.||United States|
|Cerebral Assessment Systems, LLC||United States|
|Probiotic Holdings, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Artielle ImmunoTherapeutics, Inc., please visit www.artielle.com. Company data is provided by Capital IQ. Please use this form to report any data issues.